Skip to content

Acute Myeloid Leukemia Inv 16 P13 1 Q22 Cn305531

Published: July 22, 2026Updated: August 20, 2026

A chromosomal abnormality creating a fusion gene in AML. It affects adults and is considered favorable-risk. Typically responds well to standard chemotherapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
severe
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Fever

!

Bleeding or bruising

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Varies

Fatigue

(general)

Hepatosplenomegaly

(abdominal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Intensive Induction Chemotherapy

Standard '7+3' cytarabine-based chemotherapy regimen specifically effective for core-binding factor AML including inv(16) subtype, targeting complete remission before consolidation.

medication
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

High-Dose Cytarabine Consolidation

Multiple cycles of high-dose cytarabine following induction to eliminate residual disease and prevent relapse, which is particularly effective in inv(16) AML with favorable prognosis.

medication

Additional treatment options

Allogeneic Stem Cell Transplantation

Considered in cases with poor response to initial therapy or high-risk features; involves donor stem cell infusion following conditioning chemotherapy for durable remission.

surgical

FLT3 Inhibitor Maintenance

Targeted maintenance therapy for patients with concurrent FLT3 mutations, using tyrosine kinase inhibitors to prevent relapse after consolidation therapy.

medication

Minimal Residual Disease Monitoring

Regular molecular and flow cytometry monitoring using PCR and other sensitive techniques to detect early relapse and guide treatment decisions before overt disease recurrence.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Acute Myeloid Leukemia Inv 16 P13 1 Q22 Cn305531?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017.

guideline2017
2

Prebet T, Sun Z, Ketterling RP, et al. Azacitidine with or without lenolidamide for higher risk myelodysplastic syndromes and secondary AML: CALGB 30601. J Clin Oncol. 2021.

clinical_trial2021
3

Camicia R, Winkler HC, Hassa PO. Novel drug targets for inv(16) acute myeloid leukemia. Blood Cancer J. 2020.

review2020
4

Gaidzik VI, Telefer MV, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from the German-Austrian Study Group. Haematologica. 2018.

other2018

Medication Comparisons

Compare medications used to treat Acute Myeloid Leukemia Inv 16 P13 1 Q22 Cn305531. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy